3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
122
Precursor Cell Lymphoblastic Leukemia-Lymphoma
108
Myelodysplastic Syndromes
97
Lymphoma, Non-Hodgkin
88
Leukemia, Lymphocytic, Chronic, B-Cell
81
Hodgkin Disease
81
Multiple Myeloma
80
Leukemia
72
Lymphoma, Mantle-Cell
62
Lymphoma, Follicular
58
Lymphoma
55
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
55
Myeloproliferative Disorders
52
Lymphoma, B-Cell, Marginal Zone
52
Lymphoma, Large B-Cell, Diffuse
48
Burkitt Lymphoma
48
Leukemia, Myelomonocytic, Chronic
47
Congenital Abnormalities
41
Hematologic Neoplasms
37
Lymphoma, Large-Cell, Immunoblastic
35
Leukemia, Myeloid, Accelerated Phase
34
Waldenstrom Macroglobulinemia
33
Leukemia, Myeloid, Chronic-Phase
33
Anemia, Refractory, with Excess of Blasts
32
Primary Myelofibrosis
31
Blast Crisis
28
Lymphoma, T-Cell, Cutaneous
27
Lymphoma, Large-Cell, Anaplastic
26
Leukemia, Biphenotypic, Acute
26
Dendritic Cell Sarcoma, Interdigitating
26
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
Whole-Body Irradiation
×
Clear all
NCT00368355
2020-01-21
MOHEL
Baylor College of Medicine
Phase 2
Completed
46 enrolled
12 charts